BMO Capital flags REITs risk from FMAP funding changes
BMO Capital Markets highlighted the potential risks faced by Real Estate Investment Trusts (REITs) specializing in Skilled Nursing Facilities (SNFs) due to possible changes in Federal Medical ...
BMO Capital maintains Outperform on Beam Therapeutics stock
BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears undervalued ...
IBM initiated, Southwest upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...